Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone [Yahoo! Finance]
Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)
NASDAQ:AMEX Investor Relations:
ir.canfite.com
Company Research
Source: Yahoo! Finance
Ramat Gan, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that it achieved the over 50% enrollment milestone in its Phase 2a trial of Namodenoson for pancreatic cancer.
Show less
Read more
Impact Snapshot
Event Time:
CANF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CANF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CANF alerts
High impacting Can-Fite Biopharma Ltd Sponsored ADR (Israel) news events
Weekly update
A roundup of the hottest topics
CANF
News
- Can-Fite Granted Brazilian Patent for Treatment of Sexual DysfunctionGlobeNewswire
- Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio ChangeGlobeNewswire
- Can-Fite BioPharma (NYSE:CANF) had its price target lowered by analysts at D. Boral Capital from $11.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Can-Fite Provides Update on Clinical and Financial StatusGlobeNewswire
- Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity ConferenceGlobeNewswire
CANF
Analyst Actions
- 11/4/25 - HC Wainwright
CANF
Sec Filings
- 12/23/25 - Form 6-K
- 12/16/25 - Form 6-K
- 11/21/25 - Form 424B3
- CANF's page on the SEC website